Private-equity firm Steel Partners makes unsolicited $16.75-per-share cash offer for InMode, signaling PE appetite for consolidated RF and energy-device platforms.
Steel Partners has submitted an unsolicited acquisition proposal for InMode at $16.75 per share in cash, valuing the company at approximately $1.1 billion. InMode's board has established a special committee to evaluate the offer alongside any competing bids, a standard defensive posture that typically invites other suitors.
InMode's core portfolio—Morpheus8 (fractional RF microneedling), Lumenis-integrated platforms, and body-contouring devices—generates recurring revenue through consumables (tips, handpieces) and service contracts. At current multiples, the bid reflects PE confidence in the device market's cash-generation potential, even amid competitive pressure from Cutera, Cynosure, and Synergetic.
Steel Partners values InMode at $16.75 per share, roughly $1.1 billion, betting on RF and microneedling consumables.
For independent practices, a Steel Partners ownership could signal operational restructuring, potential price increases on consumables, or aggressive MSO bundling strategies. The outcome will likely hinge on whether competing bids emerge and how InMode's Q2 revenue trajectory ($95.2–$95.4 million reported) influences valuation.
Source: original report ↗
Frequently asked questions
What does Steel Partners' bid for InMode mean for my practice's device costs?
A PE acquisition typically leads to operational restructuring and potential price increases on consumables like tips and handpieces to maximize cash flow. Independent practices may also face pressure to join MSO bundling arrangements or renegotiate service contracts at less favorable terms.
How much is Steel Partners offering for InMode per share?
Steel Partners bid $16.75 per share in cash, valuing InMode at approximately $1.1 billion. This unsolicited offer signals PE confidence in the RF and energy-device market's recurring revenue potential through consumables and service contracts.
What devices does InMode make that practices use?
InMode's core portfolio includes Morpheus8 (fractional RF microneedling), Lumenis-integrated platforms, and body-contouring devices. These generate recurring revenue through consumable sales (tips, handpieces) and ongoing service contracts.
Will InMode's board accept Steel Partners' offer?
InMode's board established a special committee to evaluate the $16.75 bid and solicit competing offers—a standard defensive tactic that typically invites other suitors. The outcome depends on competing bids and InMode's revenue trajectory, with Q2 revenue at $95.2–$95.4 million influencing final valuation.
Why is private equity interested in acquiring medical device companies like InMode?
PE firms target device platforms for their predictable recurring revenue from consumables and service contracts, which generate stable cash flow. InMode's Morpheus8 and body-contouring portfolio, combined with Lumenis integration, create an attractive consolidated RF and energy-device platform.
Business information, not medical or legal advice. Verify product status at FDA.gov.
